Compare GNL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNL | NUVB |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 56 | 291 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | GNL | NUVB |
|---|---|---|
| Price | $9.39 | $4.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.50 | ★ $11.38 |
| AVG Volume (30 Days) | 1.9M | ★ 4.6M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | ★ 8.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $190.15 |
| Revenue Next Year | N/A | $62.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $1.57 |
| 52 Week High | $10.04 | $9.75 |
| Indicator | GNL | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 39.30 |
| Support Level | $9.23 | $4.07 |
| Resistance Level | $9.75 | $5.55 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 42.95 | 37.61 |
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.